

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

04 MAR -3 PM 12:20

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ryan, Phillips, Utrecht, & MacKinnon			
2. Address <input type="checkbox"/> Check if different than previously reported 1133 Connecticut Avenue, NW, Suite 300			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name Rodney Hoppe	Telephone 202-293-1177	E-mail (optional)	5. Senate ID #
7. Client Name <input type="checkbox"/> Self Pfizer Inc.			6. House ID # 306800

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying

### INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> \$ <u>60,000</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6011 Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature

*Rodney Hoppe*

2/17/04

Signature [Handwritten Signature] \_\_\_\_\_

Printed Name and Title Rodney Hoppe, Partner \_\_\_\_\_

LD-2 (REV. 6/98)

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod information as requested. Attach additional page(s) as needed.**

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 2427, Pharmaceutical Market Access Act of 2003, all provisions  
S. 778, Medicare Rx Drug Discount and Security Act of 2003, all provisions

17. House(s) of Congress and Federal Agencies contacted

Check if None

U.S. House  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

---

Printed Name and Title Rodney Hoppe- Partner

Form LD-2 (Rev. 6/98)

Page

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod information as requested. Attach additional page(s) as needed.**

15. General issue area code PHA (One per page)

16. Specific lobbying issues

- Legislation on issues pertaining to proposed Medical Prescription Drug Benefits.
- Legislation on issues regarding FDA regulation of prescription drugs.
- H.R. 2427, Pharmaceutical Market Access Act of 2003, all provisions
- S. 778, Medicare Rx Drug Discount and Security Act of 2003, all provisions
- H.R. 1298, United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003

17. House(s) of Congress and Federal Agencies contacted  Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Printed Name and Title Rodney Hoppe- Partner

Page